Visual acuity (VA) was tested monocularly (each eye separately) under well-lit conditions with the subject's best spectacle correction at a distance of 5 meters (m) using a chart. VA was measured in decimal, with 1.0 decimal corresponding to 20/20 Snellen. A higher numeric value represents better visual acuity. No hypothesis testing was planned for this study.
VA was tested monocularly under well-lit conditions using a chart. Distance-corrected VA at 60 cm is the VA at 60 cm measured under a corrected condition in which best-corrected VA at 5 m was obtained. VA was measured in decimal, with 1.0 decimal corresponding to 20/20 Snellen. A higher numeric value represents better visual acuity. No hypothesis testing was planned for this study.
VA was tested monocularly under well-lit conditions using a chart. Distance-corrected VA at 40 cm is the VA at 40 cm measured under a corrected condition in which best-corrected VA at 5 m was obtained. VA was measured in decimal, with 1.0 decimal corresponding to 20/20 Snellen. A higher numeric value represents better visual acuity. No hypothesis testing was planned for this study.
Visit 0 preoperative: < 0.4
Group
Value
95% CI
First Eye
48
Second Eye
40
Visit 0 preoperative: 0.4 or better
Group
Value
95% CI
First Eye
20
Second Eye
27
Visit 1/1A: < 0.4
Group
Value
95% CI
First Eye
1
Second Eye
0
Visit 1/1A: 0.4 or better
Group
Value
95% CI
First Eye
67
Second Eye
67
Visit 2/2A: < 0.4
Group
Value
95% CI
First Eye
0
Second Eye
0
Visit 2/2A: 0.4 or better
Group
Value
95% CI
First Eye
68
Second Eye
67
Visit 3/3A: < 0.4
Group
Value
95% CI
First Eye
0
Second Eye
0
Visit 3/3A: 0.4 or better
Group
Value
95% CI
First Eye
68
Second Eye
67
Sponsor's own description
The purpose of this study is to evaluate the effectiveness and safety of the AcrySof® IQ PanOptix™ Intraocular Lens (IOL) Model TFNT00 when implanted to replace the natural lens following cataract removal.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a
· NA
· recruiting
NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract
· NA
· recruiting
NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV
· NA
· recruiting
NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar
· Phase 3
· recruiting
NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar
· Phase 3
· recruiting
Other Alcon Research trials
Trials by the same sponsor.
NCT06884202 — Evaluation of Delefilcon A Contact Lenses
· NA
· completed
NCT06784063 — Visual Performance With Clareon® Vivity® Intraocular Lenses (IOLs)
· NA
· completed
NCT06571656 — Evaluation of the Safety and Tolerability of Ocular Lubricants
· NA
· terminated
NCT06660290 — A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
· Phase 3
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alcon Research
Last refreshed: 24 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03090256.